List of Medications

Medication Description: Mounjaro, also known as Tirzepatide, is a newer weight loss medication that has shown promising results for Type 2 diabetes. It operates by targeting both the GLP-1 receptor and GIP receptors, effectively slowing stomach emptying and reducing appetite. Contraindications: It is advisable to avoid using Tirzepatide in cases of chronic malabsorption, pregnancy, cholestasis/history of gallbladder disease, pancreatitis, and a family history of thyroid cancer or thyroid disorders. Common Side Effects: Some common side effects of Tirzepatide may include nausea (44%), vomiting (25%), and diarrhea/GI distress (30%). Mechanism of Action: Tirzepatide engages both the GLP-1 and GIP receptors, which contribute to delaying stomach emptying, leading to a feeling of fullness for an extended period. Additionally, these receptors help suppress appetite and curb cravings. Expected Outcomes: Results from the SURMOUNT-1 trial indicate an average weight loss of 22.5% when using Tirzepatide. Further trials have demonstrated that this medication is twice as effective as Semaglutide 1.0mg.

Medication Description: Semaglutide, known by various brand names such as Wegovy, Ozempic, and Rybelsus, is a GLP-1 agonist originally developed for Type 2 Diabetes and received FDA approval in 2019. In June 2021, it was further approved as Wegovy specifically for weight loss. Contraindications: It is advised to avoid using Semaglutide in cases of a history of thyroid C-cell tumors, pregnancy, breastfeeding, and a history of anorexia/bulimia. Common Side Effects: Some common side effects of Semaglutide may include nausea (44%), vomiting (25%), and diarrhea/GI distress (30%). Mechanism of Action: Semaglutide, as a GLP-1 agonist, functions by stimulating cells in the pancreas to increase insulin levels. Additionally, it triggers the release of hormones that slow down stomach emptying, which may occasionally result in nausea. Expected Outcomes: In the STEP3 Trial conducted by Novo Nordisk, patients who incorporated Semaglutide into their robust lifestyle management routine (including 200 minutes of exercise per week, a nutri-system diet, and bimonthly visits to a nutritionist) observed a weight loss of 10-14%, which was sustained over a period of 2 years.

Medication Description: Semaglutide, known by various brand names such as Wegovy, Ozempic, and Rybelsus, is a GLP-1 agonist originally developed for Type 2 Diabetes and received FDA approval in 2019. In June 2021, it was further approved as Wegovy specifically for weight loss. Contraindications: It is advised to avoid using Semaglutide in cases of a history of thyroid C-cell tumors, pregnancy, breastfeeding, and a history of anorexia/bulimia. Common Side Effects: Some common side effects of Semaglutide may include nausea (44%), vomiting (25%), and diarrhea/GI distress (30%). Mechanism of Action: Semaglutide, as a GLP-1 agonist, functions by stimulating cells in the pancreas to increase insulin levels. Additionally, it triggers the release of hormones that slow down stomach emptying, which may occasionally result in nausea. Expected Outcomes: In the STEP3 Trial conducted by Novo Nordisk, patients who incorporated Semaglutide into their robust lifestyle management routine (including 200 minutes of exercise per week, a nutri-system diet, and bimonthly visits to a nutritionist) observed a weight loss of 10-14%, which was sustained over a period of 2 years.

Medication Description: Liraglutide, also known as Saxenda or Victoza, is a GLP-1 agonist medication that bears similarities to Semaglutide. While initially developed for Type 2 Diabetes, it has also been found to assist patients in achieving weight loss. By activating GLP-1 receptors, this medication slows down stomach emptying and sends signals to the brain to reduce appetite. Contraindications: It is advisable to avoid using Liraglutide in cases of pancreatitis, gallstones, a family history of thyroid cancer, or existing thyroid disorders. Common Side Effects: Nausea (44%), vomiting (25%), and diarrhea/GI distress (30%) are among the common side effects associated with Liraglutide. Mechanism of Action: Liraglutide, like other GLP-1 agonists, functions by stimulating pancreatic cells to increase insulin levels. Additionally, it triggers the release of hormones that slow down stomach emptying, which can occasionally result in nausea. Expected Outcomes: The SCALE Trial demonstrated that patients can achieve an average weight loss of 6.2% over a 52-week period (CI 7.5 to 4.6%) when using Liraglutide. It's important to note that individual results may vary, and the effectiveness of the medication in promoting weight loss can be influenced by factors such as adherence to the prescribed regimen, lifestyle choices, and overall health.

Medication Description: Metformin is a widely prescribed medication primarily used for managing Type 2 Diabetes. However, it has also been recognized for its potential in promoting weight loss. Contraindications: Metformin should be used with caution in individuals with impaired kidney function or a history of lactic acidosis. Common Side Effects: Some common side effects of metformin may include gastrointestinal discomfort such as nausea, vomiting, and diarrhea. These symptoms are typically temporary and tend to improve over time. Mechanism of Action: Metformin works by reducing glucose production in the liver, improving insulin sensitivity, and enhancing the uptake of glucose by muscles. These actions contribute to better blood sugar control and may help with weight loss. Expected Outcomes: When combined with a healthy diet and regular exercise, metformin has shown promise in supporting weight loss efforts. It is important to note that individual results may vary, and the effectiveness of metformin for weight loss can depend on various factors such as dosage, duration of use, and overall lifestyle habits.